This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
More than 75% of U.S. nurses have high hopes in generative AI’s promise for improving productivity. But less than half feel prepared to use it effectively.
The American Stroke Association's first major update in 7 years highlights the importance of coordinated care and expands patient access to critical treatments. It also includes the first detailed recommendations for treating stroke in pediatric patients.
Those who closely follow news and views on AI risk missing out on nine other technology categories that are changing our world just as fast. Or, as Stanford Prof. Condoleezza Rice puts it, “History will judge not only what we invented but also how and why we chose to do so.”
The use of a common medication used to end pregnancy is now in question after a federal judge in Texas struck down its legality in a shocking decision.
A new report from the Joint Commission has laid bare a dramatic increase in sentinel events, up 19% in 2022 compared to the previous year, with the majority happening in hospital settings.
"Mozarc Medical's focus will be on meaningful and innovative kidney health technologies that improve the overall patient experience and increase access to care globally," CEO Ven Manda said.
U.S. health systems are increasingly leveraging digital health to conduct their operations, but how health systems are using digital health in their strategies can vary widely.
The research fund aims to track the health of Americans for decades, with the intent of housing the long-term health information of 70% to 90% of the population.
ChatGPT isn’t capable of unilaterally guiding care for patients with cirrhosis or the liver cancer it tends to spawn, hepatocellular carcinoma (HCC). However, the large-language AI tool can competently assist clinicians.
The agency, which is charged with preventing fraud, deception and unfair business practices, said Illumina’s acquisition of Grail would stifle competition and innovation in the U.S. market for life-saving cancer tests.